In the present study, we described the interaction of succinylated human se
rum albumin (Suc-HSA), a negatively charged anti-HIV-1 active protein, with
HIV-1 gp120 and in detail with the third variable domain of gp120 (V3 loop
). To this end, different assay formats were tested in which gp120- and V3-
related peptides were presented in various configurations in order to inves
tigate the effect of the conformational structure of the V3 loop on the int
eraction with negatively charged albumins. When gp120 presented via a lecti
n was used, it was observed that Suc-HSA bound to native gp120. The binding
site appeared to be located at or near the thrombin digestion site (GPGRAF
sequence) in the V3 loop of gp120, since the cleavage of the loop resulted
in decreased binding of Suc-HSA. In addition, Suc-HSA was able to protect
the V3 region of gp120 from cleaving with thrombin. In contrast, significan
t binding of Suc-HSA to V3 loop or gp120 peptides was not observed when bot
h were presented in a fluid phase system, suggesting the involvement of a m
onovalent low affinity binding of Suc-HSA. Using overlapping peptides delin
eating the whole V3 loop immobilized to CNBr-Sepharose, we noticed that the
interaction of the V3 loop with Suc-HSA was predominantly induced by elect
rostatic interactions between positively charged linearized peptide fragmen
ts and Suc-HSA and was positively influenced by the presence of hydrophobic
amino in the V3 loop fragments as well. Moreover, the highest affinity sit
e was located at sites near the GPGRAF sequence These observations add to t
he evidence, collected earlier, that Suc-HSA interferes at the level of vir
us entry, independent of interaction with the CD4 receptor. Since the recen
tly discovered chemokine receptors are negatively charged, we can hypothesi
ze that Suc-HSA is able to prevent the positively charged V3 loop from inte
racting with these types of receptors, thereby inhibiting virus entry. BIOC
HEM PHARMACOL 57;8:889-898, 1999. (C) 1999 Elsevier Science Inc.